Literature DB >> 19050683

Management of locally advanced prostate cancer.

Heather Payne1.   

Abstract

The management of all stages of prostate cancer is an increasingly complex process and involves a variety of available treatments and many disciplines. Despite prostate-specific antigen (PSA) testing, the presentation of prostate cancer at a locally advanced stage is common in the UK, accounting for one-third of all new cases. There is no universally accepted definition of locally advanced prostate cancer; the term is loosely used to encompass a spectrum of disease profiles that show high-risk features. Men with high-risk prostate cancer generally have a significant risk of disease progression and cancer-related death if left untreated. High-risk patients, including those with locally advanced disease, present two specific challenges. There is a need for local control as well as a need to treat any microscopic metastases likely to be present but undetectable until disease progression. The optimal treatment approach will therefore often necessitate multiple modalities. The exact combinations, timing and intensity of treatment continue to be strongly debated. Management decisions should be made after all treatments have been discussed by a multidisciplinary team (including urologists, oncologists, radiologists, pathologists and nurse specialists) and after the balance of benefits and side effects of each therapy modality has been considered by the patient with regard to his own individual circumstances. This article reviews the current therapy options.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050683      PMCID: PMC3735210          DOI: 10.1038/aja.2008.9

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  28 in total

1.  Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials.

Authors:  M Roach; J Lu; M V Pilepich; S O Asbell; M Mohiuddin; R Terry; D Grignon; M Mohuidden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-06-01       Impact factor: 7.038

2.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.

Authors:  M J Zelefsky; Z Fuks; M Hunt; H J Lee; D Lombardi; C C Ling; V E Reuter; E S Venkatraman; S A Leibel
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

3.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

4.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial.

Authors:  Alan Pollack; Gunar K Zagars; George Starkschall; John A Antolak; J Jack Lee; Eugene Huang; Andrew C von Eschenbach; Deborah A Kuban; Isaac Rosen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-08-01       Impact factor: 7.038

5.  Is delayed treatment justified in carcinoma of the prostate?

Authors:  M C Parker; A Cook; P R Riddle; I Fryatt; J O'Sullivan; R J Shearer
Journal:  Br J Urol       Date:  1985-12

6.  Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate.

Authors:  Isao Hara; Hideaki Miyake; Yuji Yamada; Yoshizumi Takechi; Shoji Hara; Akinobu Gotoh; Masato Fujisawa; Hiroshi Okada; Soichi Arakawa; Toshinori Soejima; Kazuro Sugimura; Sadao Kamidono
Journal:  Int J Urol       Date:  2002-06       Impact factor: 3.369

7.  Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy.

Authors:  M J Zelefsky; S A Leibel; C M Burman; G J Kutcher; A Harrison; L Happersett; Z Fuks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-07-01       Impact factor: 7.038

8.  Conservative management with symptomatic treatment and delayed hormonal manipulation is justified in men with locally advanced carcinoma of the prostate.

Authors:  A Rana; G D Chisholm; M Khan; H M Rashwan; R A Elton
Journal:  Br J Urol       Date:  1994-11

9.  Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study.

Authors:  A Henderson; S E M Langley; R W Laing
Journal:  Clin Oncol (R Coll Radiol)       Date:  2003-09       Impact factor: 4.126

10.  Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.

Authors:  David P Dearnaley; Matthew R Sydes; John D Graham; Edwin G Aird; David Bottomley; Richard A Cowan; Robert A Huddart; Chakiath C Jose; John Hl Matthews; Jeremy Millar; A Rollo Moore; Rachel C Morgan; J Martin Russell; Christopher D Scrase; Richard J Stephens; Isabel Syndikus; Mahesh K B Parmar
Journal:  Lancet Oncol       Date:  2007-06       Impact factor: 41.316

View more
  5 in total

1.  The predictability of T3 disease in staging MRI following prostate biopsy decreases in patients with high initial PSA and Gleason score.

Authors:  Young Hwii Ko; Deuk Jae Sung; Sung Gu Kang; Seok Ho Kang; Jeong Gu Lee; Je Jong Kim; Jun Cheon
Journal:  Asian J Androl       Date:  2011-03-07       Impact factor: 3.285

2.  Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks.

Authors:  Juan-Jie Bo; Chao Zhang; Lian-Hua Zhang; Ping Liu; Jian-Jun Sha; Jian-Wei Lv; Dong-Ming Liu; Yi-Ran Huang; Zheng Li
Journal:  Asian J Androl       Date:  2011-07-25       Impact factor: 3.285

3.  The biochemical efficacy of primary cryoablation combined with prolonged total androgen suppression compared with radiotherapy on high-risk prostate cancer: a 3-year pilot study.

Authors:  Young Hwii Ko; Seok Ho Kang; Young Je Park; Hong Seok Park; Du Geon Moon; Jeong Gu Lee; Duck Ki Yoon; Je Jong Kim; Jun Cheon
Journal:  Asian J Androl       Date:  2010-08-16       Impact factor: 3.285

4.  Perioperative complications of radical retropubic prostatectomy in patients with locally advanced prostate cancer: a comparison with clinically localized prostate cancer.

Authors:  Xu-Dong Yao; Xiao-Jun Liu; Shi-Lin Zhang; Bo Dai; Hai-Liang Zhang; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2012-12-10       Impact factor: 3.285

5.  Impact of cancer service centralisation on the radical treatment of men with high-risk and locally advanced prostate cancer: A national cross-sectional analysis in England.

Authors:  Matthew G Parry; Arunan Sujenthiran; Thomas E Cowling; Julie Nossiter; Paul Cathcart; Noel W Clarke; Heather Payne; Ajay Aggarwal; Jan van der Meulen
Journal:  Int J Cancer       Date:  2019-01-17       Impact factor: 7.396

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.